How many Dupilumab clinical trials are there?

230 Dupilumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 54 are actively recruiting participants. 105 are marked completed.

Are Dupilumab clinical trials recruiting in 2026?

Yes — 54 Dupilumab trials are actively recruiting in 2026, with 346 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Dupilumab being studied for?

Dupilumab is being studied for Atopic Dermatitis, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Dermatitis, Atopic, Eosinophilic Esophagitis and 130 more. The trials are grouped by indication on this page.

What phase is Dupilumab in?

Dupilumab clinical trials span 56 Phase 4, 50 Phase 3, 51 Phase 2, 12 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Dupilumab clinical trials?

The lead sponsor across the most Dupilumab trials is Sanofi, with 85 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Dupilumab Clinical Trials (2026): 230 Studies for Atopic Dermatitis & Asthma

Creator: Hipa.ai Research
Published: 2026-05-29T17:22:19.385Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

230 Dupilumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 90 indications (including Atopic Dermatitis & Asthma) and 50,336 total planned enrollment. 50 Phase 3 Dupilumab trials and 51 Phase 2, 56 Phase 4 are listed. 63 Dupilumab clinical trials are actively recruiting at 346 U.S. sites across 40 states. Most recent activity: NCT06501807 (Jan 2035).

Where to Participate: All Dupilumab Trial Sites in the U.S. (346 sites across 40 states)

Every actively recruiting Dupilumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Allervie Clinical Research	Birmingham35209	NCT06868212	Map
AL	Cahaba Derm and skin hlth ctr 27	Birmingham35244	NCT06868212	Map
AL	Cahaba Dermatology & Skin Health Center /ID# 263855	Birmingham35244	NCT06389136	Map
AL	University of Alabama at Birmingham - School of Medicine- Site Number : 8400003	Birmingham35233	NCT07053423	Map
AZ	Research Solutions of Arizona	Litchfield Park85340	NCT06868212	Map
AZ	Peak Dermatology	Payson85541	NCT06868212	Map
AZ	Avacare Center for Dermatology	Phoenix85044	NCT06868212	Map
AZ	Phoenix Children's Hospital- Site Number : 8400001	Phoenix85016	NCT06191315	Map
AZ	Phoenix Childrens Hospital	Phoenix85016	NCT06693531	Map
AZ	Phoenix Childrens Hospital	Phoenix85016	NCT07112378	Map
AZ	Premier Allergy Asthma And Immunology	Phoenix85032	NCT06868212	Map
AZ	Mayo Clinic	Scottsdale85259	NCT06385236	Map
AZ	One Of A Kind Clinical Research Center - Scottsdale /ID# 278675	Scottsdale85253	NCT06389136	Map
AZ	Orso Health	Scottsdale85254	NCT06868212	Map
AR	Clin Trial Inst of Northwest AR	Fayetteville72703	NCT06868212	Map
AR	Clinical Trials Institute - Northwest Arkansas /ID# 267290	Fayetteville72703	NCT06389136	Map
AR	Acuro Research Inc	Little Rock72205	NCT06868212	Map
AR	Applied Research Center Of Arkansas /ID# 268547	Little Rock72205	NCT06461897	Map
AR	Arkansas Childrens Hospital	Little Rock72202	NCT06693531	Map
CA	Private Practice - Dr. Tooraj Raoof /ID# 263849	Encino91436	NCT06389136	Map
CA	First OC Dermatology	Fountain Valley92708	NCT06868212	Map
CA	First OC Dermatology /ID# 263349	Fountain Valley92708	NCT06389136	Map
CA	Ctr for Dermatology Clinical Res	Fremont95438	NCT06868212	Map
CA	NorCal Medical Research /ID# 278397	Greenbrae94904	NCT06389136	Map
CA	Allergy and Asthma Specialists Group	Huntington Beach92647	NCT06868212	Map
CA	University of California, Irvine	Irvine92697	NCT05551793	Map
CA	University of California, Irvine	Irvine92697	NCT05866562	Map
CA	Modena Allergy + Asthma- Site Number : 8400038	La Jolla92037	NCT05263206	Map
CA	University of California San Diego (UCSD) Health Medical center	La Jolla92037	NCT06665971	Map
CA	University of California, San Diego	La Jolla92093	NCT06385236	Map
CA	Ark Clinical Research	Long Beach90815	NCT06868212	Map
CA	Orso Health	Long Beach90808	NCT06868212	Map
CA	California Allergy and Asthma Medical Group	Los Angeles90025	NCT06868212	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT06868212	Map
CA	Allergy & Asthma Associates of Southern California - Mission Viejo /ID# 266574	Mission Viejo92691	NCT06389136	Map
CA	One Of A Kind Clinical Research	Napa94558	NCT06868212	Map
CA	University of California, San Francisco	Oakland94609	NCT06693531	Map
CA	Dermatologist Medical Group of North County- Profound Research /ID# 266512	Oceanside92056	NCT06389136	Map
CA	Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021	Palo Alto94304	NCT06293053	Map
CA	Stanford University School of Medicine - Palo Alto /ID# 269622	Palo Alto94304	NCT06461897	Map
CA	Comprehensive Dermatology Center of Pasadena /ID# 281014	Pasadena91105	NCT06389136	Map
CA	Empire Clinical Research	Pomona91767	NCT06868212	Map
CA	Mission Dermatology Center- Site Number : 8400011	Rancho Santa Margarita92688	NCT06293053	Map
CA	Allergy and Asthma Consultants	Redwood City94063	NCT06868212	Map
CA	Stanford University School of Medicine - Redwood City /ID# 263776	Redwood City94063	NCT06389136	Map
CA	Norcal Clinical Research	Rocklin95765	NCT06868212	Map
CA	Peninsula Research Associates	Rolling Hills Estates90274	NCT06868212	Map
CA	Integrative Skin Science and Res	Sacramento95815	NCT06868212	Map
CA	Integrative Skin Science and Research /ID# 264537	Sacramento95815	NCT06389136	Map
CA	Integrative Skin Science and Research /ID# 265108	Sacramento95815	NCT06461897	Map
CA	UC Davis Neuromuscular Research Center	Sacramento95817	NCT06868212	Map
CA	Therapeutics Clinical Research	San Diego92123	NCT06868212	Map
CA	University of California San Diego	San Diego92093	NCT05866562	Map
CA	West Dermatology La Jolla /ID# 265014	San Diego92121	NCT06389136	Map
CA	University of California, San Francisco	San Francisco94143	NCT05858619	Map
CA	Dermatology Institute and Skin Care	Santa Monica90404	NCT06868212	Map
CA	Clinical Trials Research Institute /ID# 263846	Thousand Oaks91320	NCT06389136	Map
CA	Integrated Research of Inland Inc	Upland91786	NCT06868212	Map
CA	Allergy and Asthma Clin Res Inc	Walnut Creek94598	NCT06868212	Map
CO	Children's Hospital Colorado	Aurora80045	NCT07112378	Map
CO	Children's Hospital Colorado/University of Colorado School of Medicine	Aurora80045	NCT06705387	Map
CO	Childrens Hospital Colorado	Aurora80045	NCT06693531	Map
CO	University of Colorado Hospital - Aurora	Aurora80045	NCT06868212	Map
CO	Asthma and Allergy Associates P C	Colorado Springs80907	NCT06868212	Map
CO	Colorado ENT and Allergy	Colorado Springs80909	NCT06868212	Map
CO	Skylight Health Res Inc Color Spr	Colorado Springs80917	NCT06868212	Map
CT	UCONN Health Dermatology	Farmington06030-2840	NCT06868212	Map
CT	Yale School of Medicine	New Haven06510	NCT06693531	Map
CT	Yale University	New Haven06520	NCT06385236	Map
CT	Yale University School of Medicine /ID# 263836	New Haven06510	NCT06389136	Map
DC	FoxHall Dermatology- Site Number : 8400042	Washington D.C.20016	NCT05263206	Map
DC	Howard University Hospital Division of Geriatrics	Washington D.C.20059	NCT06868212	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	Palm Harbor Dermatology- Site Number : 8400024	Belleair32756	NCT05263206	Map
FL	Skin Care Research Boca Raton /ID# 263733	Boca Raton33486-2269	NCT06389136	Map
FL	Skin Care Research Inc	Boca Raton33486	NCT06868212	Map
FL	TrueBlue Clinical Research - Brandon /ID# 265037	Brandon33511	NCT06389136	Map
FL	Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 8400005	Coral Gables33146	NCT06293053	Map
FL	Pediatric Skin Research /ID# 266308	Coral Gables33146	NCT06461897	Map
FL	Life Clinical Trials - Coral Springs /ID# 267195	Coral Springs33071	NCT06389136	Map
FL	Life Clinical Trials - Coral Springs- Site Number : 8400018	Coral Springs33071	NCT06293053	Map
FL	Allervie Clinical Research - Destin- Site Number : 8400016	Destin32541	NCT06191315	Map
FL	Omnicure Clinical Research	Doral33172	NCT06868212	Map
FL	FXM Clinical Research Ft Laud	Fort Lauderdale33308	NCT06868212	Map
FL	FXM Clinical Research Ft. Lauderdale /ID# 280911	Fort Lauderdale33308	NCT06389136	Map
FL	Direct Helpers Research Center- Site Number : 8400015	Hialeah33012	NCT06293053	Map
FL	Skin Care Research - Hollywood /ID# 263739	Hollywood33021-6748	NCT06389136	Map
FL	Skin Care Research LLC	Hollywood33021	NCT06868212	Map
FL	Jacksonville Center for Clinical Research	Jacksonville32216	NCT06868212	Map
FL	SunCoast Skin Solutions - Lutz- Site Number : 8400008	Lutz33558	NCT06293053	Map
FL	GSI Clinical Research, LLC /ID# 263760	Margate33063-7011	NCT06389136	Map
FL	EMDA Clinical Research- Site Number : 8400026	Miami33126	NCT06191315	Map
FL	FAX Pharma Clinical Research /ID# 280915	Miami33146	NCT06389136	Map
FL	Finlay Medical Research- Site Number : 8400010	Miami33126	NCT07053423	Map
FL	FXM Clinical Res Miami LLC	Miami33175	NCT06868212	Map
FL	International Dermatology Research /ID# 264961	Miami33144	NCT06389136	Map
FL	Lenus Research and Medical Group /ID# 263779	Miami33172	NCT06389136	Map
FL	Miami Dade Medical Research	Miami33176	NCT06868212	Map
FL	Research Associates of South Florida /ID# 267291	Miami33134	NCT06389136	Map
FL	Sullivan Dermatology /ID# 263537	Miami33162	NCT06389136	Map
FL	University of Miami Hospital- Site Number : 8400011	Miami33136	NCT05263206	Map
FL	University of MiamiHealth System	Miami33125	NCT06868212	Map
FL	FXM Clin Res Miramar LLC	Miramar33027	NCT06868212	Map
FL	Fxm Clinical Research - Miramar /ID# 280934	Miramar33027	NCT06389136	Map
FL	Ziaderm Research LLC	North Miami Beach33162	NCT06868212	Map
FL	Gastroenterology of Greater Orlando	Orange City32763	NCT06693531	Map
FL	Orlando Health	Orlando32806	NCT06693531	Map
FL	AllerVie Health	Panama32405	NCT06868212	Map
FL	Sarasota Clinical Research	Sarasota34233	NCT06868212	Map
FL	Global Clinical Professionals (GCP) /ID# 266474	St. Petersburg33705	NCT06389136	Map
FL	Lenus Research and Med Group LLC	Sweetwater33172	NCT06868212	Map
FL	Alliance Clinical Research of Tampa /ID# 264531	Tampa33615	NCT06389136	Map
FL	Asthma Allergy Immunology Clin Res	Tampa33613	NCT06868212	Map
FL	Olympian Clinical Research	Tampa33609	NCT06868212	Map
FL	Skin Care Research - Tampa /ID# 263750	Tampa33607-6438	NCT06389136	Map
FL	University of South Florida	Tampa33613	NCT06369467	Map
FL	USF Health- Site Number : 8400003	Tampa33606	NCT06293053	Map
FL	Encore Medical Research - Weston /ID# 278491	Weston33331	NCT06389136	Map
FL	Conquest Research	Winter Park32789	NCT06868212	Map
GA	Emory University - Winship Cancer Institute	Atlanta30322	NCT06369467	Map
GA	GI Care for Kids LLC	Atlanta30342	NCT06693531	Map
GA	GI Care for Kids LLC	Atlanta30342	NCT07112378	Map
GA	AllerVie Clin Res Columbus GA	Columbus31904	NCT06868212	Map
GA	Centricity Research Columbus Dermatology /ID# 266529	Columbus31904	NCT06389136	Map
GA	Private Practice - Dr. David Kavtaradze- Site Number : 8400017	Cordele31015	NCT07053423	Map
GA	Cleaver Medical Group	Cumming30040	NCT06868212	Map
GA	Cleaver Medical Group Dermatology /ID# 263788	Dawsonville30534	NCT06389136	Map
GA	Southeast Dermatology Specialists	Douglasville30135	NCT06868212	Map
GA	Skin Care Physicians of Georgia - Macon- Site Number : 8400030	Macon31217	NCT05263206	Map
GA	Aeroallergy Research Laboratories	Savannah31406	NCT06868212	Map
GA	Aeroallergy Research Laboratory /ID# 267247	Savannah31406	NCT06461897	Map
GA	Aeroallergy Research Laboratory- Site Number : 8400036	Savannah31406	NCT05263206	Map
ID	Treasure Valley Medical Research /ID# 263738	Boise83706	NCT06389136	Map
ID	Treasure Valley Medical Research /ID# 266838	Boise83706	NCT06461897	Map
ID	The Allergy Group-Meridian Clinic	Meridian83642	NCT06868212	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT05649098	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT05866562	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT06693531	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400011	Chicago60611	NCT06191315	Map
IL	DeNova Research /ID# 264513	Chicago60610	NCT06389136	Map
IL	Lurie Children's Hospital/Northwestern University	Chicago60611	NCT05042258	Map
IL	Northwestern University Feinberg School of Medicine	Chicago60611	NCT05866562	Map
IL	Northwestern University Feinberg School of Medicine	Chicago60611	NCT06892704	Map
IL	Northwestern University Feinberg School of Medicine /ID# 264983	Chicago60611-2927	NCT06389136	Map
IL	Northwestern University Feinberg School of Medicine /ID# 265117	Chicago60611-2927	NCT06461897	Map
IL	NW Uni C and T Sciences Ins	Chicago60611	NCT06868212	Map
IL	Midwest Allergy Sinus Asthma SC	Normal61761	NCT06868212	Map
IL	Sneeze Wheeze & Itch Associates /ID# 267238	Normal61761	NCT06461897	Map
IL	Clinical Res Ctr of S Illinois	O'Fallon62269	NCT06868212	Map
IL	Asthma and Allergy Center of Chicago S C	River Forest60305	NCT06868212	Map
IL	Endeavor Health Clinical Trials Center	Skokie60077	NCT06868212	Map
IL	Endeavor Health, Skokie Campus	Skokie60077	NCT06693531	Map
IL	Accellacare Duly Health and Care	Wheaton60189	NCT06868212	Map
IN	Deaconess Clin Allerg Res Inst	Evansville47715	NCT06868212	Map
IN	Dawes Fretzin Clinical Research- Site Number : 8400007	Indianapolis46256	NCT05263206	Map
IN	Dawes Fretzin, LLC /ID# 265097	Indianapolis46256	NCT06461897	Map
IN	Southern IN Clinical Trials	New Albany47150	NCT06868212	Map
IN	Options Research Group /ID# 264564	West Lafayette47906	NCT06389136	Map
IA	McFarland Clinic PC	Ames50010	NCT06868212	Map
KY	Equity Medical LLC	Bowling Green42104	NCT06868212	Map
KY	Equity Medical, LLC /ID# 268270	Bowling Green42104	NCT06461897	Map
KY	Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400031	Louisville40241	NCT05263206	Map
KY	Family Allergy And Asthma Rsch Inst	Louisville40215	NCT06868212	Map
KY	Allergy & Asthma Specialists, P.S.C.	Owensboro42301	NCT06693531	Map
KY	Allergy and Asthma Specialist P S C	Owensboro42301	NCT06868212	Map
KY	Allergy and Asthma Specialist- Site Number : 8400002	Owensboro42301	NCT06191315	Map
LA	Ochsner Health Center	Baton Rouge70816	NCT06868212	Map
LA	Velocity Clinical Research	Lafayette70508	NCT06868212	Map
LA	Tulane University School of Medicine- Site Number : 8400045	New Orleans70112	NCT05263206	Map
MD	Chesapeake Clinical Research Inc	Baltimore21236	NCT06868212	Map
MD	Johns Hopkins Bayview Medical Center- Site Number : 8400009	Baltimore21224	NCT07053423	Map
MD	Johns Hopkins Hospital- Site Number : 8400020	Baltimore21287	NCT05263206	Map
MD	Johns Hopkins U School of Med	Baltimore21205	NCT06868212	Map
MD	Johns Hopkins Univerisity	Baltimore21210	NCT06116526	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT06477653	Map
MD	Institute for Asthma and Allergy PC	Chevy Chase20815	NCT06868212	Map
MD	AllerVie Clin Res Glenn Dale	Glenn Dale20769	NCT06868212	Map
MD	Maryland Allergy & Asthma Center /ID# 268032	Lanham20706	NCT06461897	Map
MD	DermAssociates - Rockville /ID# 266457	Rockville20850	NCT06461897	Map
MA	Boston Childrens Hospital	Boston02115	NCT06693531	Map
MA	Boston Specialists /ID# 265810	Boston02111-1901	NCT06389136	Map
MA	Boston Specialists LLC	Boston02111	NCT06868212	Map
MA	Boston Specialists, Chinatown Office	Boston02111	NCT06693531	Map
MA	Brigham & Women's Hospital- Site Number : 8400014	Boston02115	NCT07053423	Map
MA	Massachusetts General Hospital	Boston02114	NCT06369467	Map
MA	Massachusetts General Hospital	Boston02114	NCT06693531	Map
MA	Massachusetts General Hospital	Boston02114	NCT07112378	Map
MA	Regeneron Research Site	Boston02215	NCT03936335	Map
MA	Beacon Clinical Research /ID# 263843	Quincy02169	NCT06389136	Map
MI	ClinSite Inc	Ann Arbor48106-0525	NCT06868212	Map
MI	University of Michigan	Ann Arbor48109	NCT05268107	Map
MI	Derm Institute West Michigan PLLC	Caledonia49316	NCT06868212	Map
MI	Henry Ford Hospital	Detroit48202	NCT06868212	Map
MI	Henry Ford Medical Center - New Center One /ID# 263522	Detroit48202-3046	NCT06389136	Map
MI	Revival Research Institute	Troy48084	NCT06868212	Map
MI	Somerset Skin Centre	Troy48084	NCT06868212	Map
MN	Tareen Dermatology - Eagan- Site Number : 8400022	Eagan55123	NCT06293053	Map
MN	Clinical Research Institute	Minneapolis55402	NCT06868212	Map
MN	University of Minnesota	Minneapolis55455	NCT06868212	Map
MN	Mayo Clinic - Rochester	Rochester55905	NCT06868212	Map
MN	Mayo Clinic in Rochester - Minnesota- Site Number : 8400008	Rochester55905	NCT06191315	Map
MO	ENT and Allergy Center of Missouri	Columbia65201	NCT06868212	Map
MO	MediSearch Clinical Trials /ID# 263579	Saint Joseph64506	NCT06389136	Map
MO	MediSearch Clinical Trials- Site Number : 8400004	Saint Joseph64506	NCT06293053	Map
MO	The Clinical Research Center	St Louis63141	NCT06868212	Map
MO	Washington University	St Louis63141	NCT06868212	Map
MO	Washington University School of Medicine - St. Louis /ID# 268545	St Louis63130	NCT06461897	Map
NE	The Asthma and Allergy Center- Site Number : 8400014	Bellevue68123	NCT05263206	Map
NE	Physician Research Collaboration, LLC /ID# 263583	Lincoln68516	NCT06389136	Map
NE	Somnos Clinical Research	Lincoln68510	NCT06868212	Map
NE	Skin Specialists /ID# 263345	Omaha68144	NCT06389136	Map
NE	Skin Specialists /ID# 266331	Omaha68144	NCT06461897	Map
NV	Allergy and Asthma Center of Las Vegas	Las Vegas89128	NCT06868212	Map
NV	Las Vegas Dermatology	Las Vegas89144	NCT06868212	Map
NV	Las Vegas Dermatology /ID# 265801	Las Vegas89144	NCT06389136	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 263771	Reno89509	NCT06389136	Map
NH	Dartmouth Hitchcock Medical Center - Old Etna Road /ID# 263840	Lebanon03766	NCT06389136	Map
NJ	Hudson Essex Allergy-Circuit Clinical	Belleville07109	NCT06868212	Map
NJ	Circuit Clinical Mercer Algy Pulm	Hamilton08619	NCT06868212	Map
NJ	Allergy Asthma Assoc Monmouth	Little Silver07739	NCT06868212	Map
NJ	Allergy Partners of New Jersey PC	Ocean Township07712	NCT06868212	—
NJ	Circuit Clinical	Riverdale07457	NCT06868212	Map
NY	UBMD Pediatrics- Site Number : 8400013	Buffalo14203	NCT06191315	Map
NY	Boston Children's Health Physicians - Hawthorne- Site Number : 8400010	Hawthorne10532	NCT06191315	Map
NY	Steven And Alexandra Cohen Children's Medical Center Of New York	Lake Success11042	NCT06693531	Map
NY	Equity Medical, LLC /ID# 265814	New York10023-7340	NCT06389136	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT05551793	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT05866562	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06088771	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06369467	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06693531	Map
NY	Mount Sinai - Union Square- Site Number : 8400034	New York10003	NCT05263206	Map
NY	Mount Sinai Health System	New York10029	NCT06637306	Map
NY	Weil Cornell Medicine NYP	New York10021	NCT06693531	Map
NY	Weill Cornell Medicine	New York10065	NCT07112378	Map
NY	Weill Cornell Medicine /ID# 265793	New York10065	NCT06389136	Map
NY	Gastroenterology Group of Rochester LLP	Rochester14618	NCT06693531	Map
NY	UR Dermatology at College Town	Rochester14620	NCT05551793	Map
NY	Equity Medical	The Bronx10455	NCT06868212	Map
NY	Montefiore Medical Center	The Bronx10461	NCT05246267	Map
NY	Montefiore Medical Center	The Bronx10467	NCT06868212	Map
NC	Allergy Partners Of West NC	Asheville28801	NCT06868212	Map
NC	UNC Children's Hospital- Site Number : 8400005	Chapel Hill27514	NCT06191315	Map
NC	UNC DermatologyandSkinCancer Ctr	Chapel Hill27516	NCT06868212	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599	NCT06693531	Map
NC	University of North Carolina, Bioinformatics Building	Chapel Hill27599	NCT07112378	Map
NC	American Health Research - Charlotte- Site Number : 8400013	Charlotte28277	NCT07053423	Map
NC	Piedmont Plastic Surgery and Dermatology - Huntersville /ID# 266545	Huntersville28078-7961	NCT06389136	Map
NC	Virtual Research Coordination Center	Wilmington28401-3331	NCT07316114	Map
NC	Atrium Health / Wake Forest University School of Medicine	Winston-Salem27157	NCT06693531	Map
NC	Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004	Winston-Salem27103	NCT07053423	Map
ND	AXIS Clinicals - Fargo- Site Number : 8400013	Fargo58103	NCT06293053	Map
ND	AXIS Clinicals - Fargo- Site Number : 8400037	Fargo58103	NCT05263206	Map
OH	Akron Children's Hospital	Akron44308	NCT06226610	Map
OH	Optima Research - Boardman- Site Number : 8400039	Boardman44512	NCT05263206	Map
OH	DOCS Clinical Research - Canal Winchester /ID# 268271	Canal Winchester43110-2069	NCT06461897	Map
OH	Bernstein Clinical Research Center	Cincinnati45231	NCT06868212	Map
OH	Cincinnati Children's Hospital Medical Center- Site Number : 8400004	Cincinnati45229	NCT06191315	Map
OH	University Hospitals Cleveland Medical Center- Site Number : 8400015	Cleveland44106	NCT06191315	Map
OH	CR Services Acquisition US	Columbus43213	NCT06868212	Map
OH	Wright State Physicians Health Center /ID# 268841	Fairborn45324	NCT06461897	Map
OH	Wright State University	Fairborn45324	NCT06868212	Map
OH	Toledo Institute of Clinical Research	Toledo43617	NCT06868212	Map
OK	Unity Clinical Research	Oklahoma City73118	NCT06868212	Map
OK	Vital Prospects Clinical Research Institute	Tulsa74136	NCT06868212	Map
OK	Vital Prospects Clinical Research Institute - Tulsa- Site Number : 8400002	Tulsa74136	NCT06293053	Map
OR	Oregon Health and Science University /ID# 263736	Portland97239	NCT06389136	Map
OR	Oregon Health and Science University /ID# 266483	Portland97239	NCT06461897	Map
OR	Oregon Health Sciences University	Portland97239	NCT06868212	Map
OR	Oregon Medical Research Center	Portland97223	NCT06868212	Map
PA	Clinical Research Associates of Central Pennsylvania- Site Number : 8400002	DuBois15801	NCT07053423	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT07112378	Map
PA	Clinical Research of Philadelphia /ID# 264972	Philadelphia19114	NCT06389136	Map
PA	The Children's Hospital of Philadelphia	Philadelphia19104	NCT06369467	Map
PA	The Children's Hospital of Philadelphia	Philadelphia19104	NCT06693531	Map
PA	Allergy and Clinical Immunology Associates	Pittsburgh15241	NCT06868212	Map
PA	The University of Pittsburgh Asthma Institute at UPMC	Pittsburgh15213	NCT04743791	Map
PA	University of Pittsburgh Medical Center /ID# 264526	Pittsburgh15213	NCT06389136	Map
PA	Dermatology Associates of Plymouth Meeting /ID# 267286	Plymouth Meeting19462	NCT06389136	Map
SC	Medical Univ Of SC Medical Ctr	Charleston29425	NCT06868212	Map
SC	Medical University of South Carolina	Charleston29425	NCT06693531	Map
SC	Medical University of South Carolina	Charleston29425	NCT07112378	Map
SC	Medical University of South Carolina /ID# 263655	Charleston29425	NCT06389136	Map
SC	Medical University of South Carolina /ID# 265113	Charleston29425	NCT06461897	Map
SC	Columbia Dermatology & Aesthetics- Site Number : 8400047	Columbia29212	NCT05263206	Map
SC	Allergic Disease and Asthma Center	Greenville29607	NCT06868212	Map
SC	Tribe Clinical Research LLC	Greenville29601	NCT06868212	Map
SC	Charleston ENT and Allergy	North Charleston29406	NCT06868212	Map
SC	National Allergy and Asthma - North Charleston - Northside Drive- Site Number : 8400032	North Charleston29420	NCT05263206	Map
SC	National Allergy and Asthma Research LLS	North Charleston29420	NCT06868212	Map
SC	Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 267185	Spartanburg29307	NCT06389136	Map
SD	Health Concepts /ID# 263383	Rapid City57702	NCT06389136	Map
TN	International Clinical Research Tennessee LCC	Murfreesboro37130	NCT06868212	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06693531	Map
TN	Vanderbilt University Medical Center- Site Number : 8400024	Nashville37232	NCT06191315	Map
TX	Arlington Center for Dermatology	Arlington76011	NCT06868212	Map
TX	Arlington Research Center, Inc /ID# 263665	Arlington76011	NCT06389136	Map
TX	Arlington Research Center, Inc /ID# 266330	Arlington76011	NCT06461897	Map
TX	Dell Children's Medical Center- Site Number : 8400007	Austin78723	NCT06293053	Map
TX	Orion Clinical Research	Austin78759	NCT06868212	Map
TX	REX Clinical Trials - Beaumont- Site Number : 8400011	Beaumont77701	NCT07053423	Map
TX	Bellaire Dermatology Associates	Bellaire77401	NCT06868212	Map
TX	South Texas Medical Research Institute - TTS Research- Site Number : 8400022	Boerne78006	NCT06191315	Map
TX	Driscoll Children's Hospital- Site Number : 8400017	Corpus Christi78411	NCT06293053	Map
TX	Studies in Dermatology LLC /ID# 263335	Cypress77429	NCT06389136	Map
TX	Dermatology Treatment and Research Center /ID# 265812	Dallas75230	NCT06389136	Map
TX	Modern Research Associates /ID# 263852	Dallas75231	NCT06389136	Map
TX	Pharma Research and Amp Consult	Dallas75231	NCT06868212	Map
TX	Reveal Research Institute	Dallas75230	NCT06868212	Map
TX	3A Research - East location /ID# 267622	El Paso79925	NCT06461897	Map
TX	Western Sky Medical Research	El Paso79924	NCT06868212	Map
TX	Cook Children's Medical Center	Fort Worth76104	NCT07112378	Map
TX	Baylor College of Medicine	Houston77030	NCT06693531	Map
TX	Center for Clinical Studies	Houston77030	NCT06868212	Map
TX	Texas Children's Hospital- Site Number : 8400027	Houston77030	NCT06191315	Map
TX	BRCR Global - Katy /ID# 267304	Katy77450	NCT06389136	Map
TX	Sante Clinical Research	Kerrville78028	NCT06868212	Map
TX	Prime Clinical Research - Mansfield - East Broad Street /ID# 268042	Mansfield76063	NCT06461897	Map
TX	Sms Clinical Research /ID# 278676	Mesquite75149	NCT06389136	Map
TX	Andante Research	San Antonio78229	NCT06868212	Map
TX	Biogenics Research Chamber	San Antonio78229	NCT05720325	Map
TX	Progressive Clinical Research - San Antonio /ID# 267262	San Antonio78229	NCT06461897	Map
TX	RFSA Dermatology	San Antonio78213	NCT06868212	Map
TX	Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400020	San Antonio78218	NCT06293053	Map
TX	Texas Dermatology and Laser Specialists /ID# 267249	San Antonio78218	NCT06461897	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT05720325	Map
TX	Complete Dermatology - Sugar Land- Site Number : 8400046	Sugar Land77479	NCT05263206	Map
TX	Stride Clinical Research /ID# 267331	Sugar Land77479	NCT06389136	Map
TX	The Woodlands Dermatology Associates /ID# 266547	The Woodlands77380	NCT06389136	Map
TX	Dermatology Associates of Tyler /ID# 264980	Tyler75703	NCT06389136	Map
UT	Tanner Clinic	Layton84041	NCT06693531	Map
UT	University Of Utah	Murray84107	NCT06868212	Map
UT	Allergy Associates of Utah	Sandy City84093	NCT06868212	Map
UT	Jordan Valley Dermatology & Research Center /ID# 267092	South Jordan84095	NCT06461897	Map
VA	University of Virginia	Charlottesville22908	NCT04380038	Map
VA	University of Virginia	Charlottesville22908	NCT06693531	Map
VA	University of Virginia	Charlottesville22908	NCT07112378	Map
VA	University of Virginia Health System	Charlottesville22908	NCT05094570	Map
VA	Forefront Dermatology	Vienna22182	NCT06868212	Map
WA	Bellingham Asthma Allergy and Immunology	Bellingham98225	NCT06868212	Map
WA	Seattle Children's Home Health Company	Seattle98105	NCT06693531	Map
WV	West Virginia Research Institute - Morgantown /ID# 264930	Morgantown26505	NCT06389136	Map
WV	West Virginia University Hospitals /ID# 265114	Morgantown26506	NCT06461897	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06693531	Map
WI	Wisconsin Medical Center /ID# 267236	Milwaukee53226	NCT06461897	Map

Dupilumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	temporarily not available	approved for marketing	Total
Early P1	2		1	1	1						5
P1	1	2		8			1				12
P1/P2	1	1					1				3
P2	9	6		28	5			3			51
P2/P3		1		2				1			4
P3	8	3		37	1	1					50
P4	12	10		21	1	2	5	5			56
N/A	19	8	1	8	1		2	6	1	3	49

Recruiting Dupilumab clinical trials (63)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06501807	BIOPOSE2BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry	N/A	Rhinosinusitis Chronic	900	Jul 2024
NCT05649098	Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders	Early P1	Skin Diseases	30	Jun 2023
NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	Atopic Dermatitis	50	May 2026
NCT07277322	Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases	P1/P2	Metastatic Colorectal Cancer	24	Jun 2026
NCT06461897	Start UpA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	P3	Atopic Dermatitis	675	Aug 2024
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT06693531	EDESIAA U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care	—	Eosinophilic Esophagitis (EoE)	350	Nov 2024
NCT06743581	Dupi-CemiPhase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer	N/A	Non-Small Cell Lung Cancer	24	Feb 2025
NCT07309614	HOTHOTA Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma	P3	Asthma Control	150	Jan 2026
NCT06818019	WIDUSAWithdrawal of Dupilumab in Severe Asthma	P4	Severe Asthma	205	Apr 2025
NCT03358693	MSIDMolecular Signatures in Inflammatory Skin Disease	—	Atopic Dermatitis	300	Jan 2017
NCT07316114	DEDICATIONA Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria	—	Chronic Spontaneous Urticaria	400	Mar 2026
NCT07052396	ANEMOStudy to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions	—	Chronic Obstructive Pulmonary Disease (COPD)	350	Jul 2025
NCT06695897	ProMEALA Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany	—	Eosinophilic Esophagitis	150	Dec 2024
NCT05866562	PEDALDupilumab in the Treatment of Pediatric Alopecia Areata	P2	Alopecia Areata	76	Jul 2024
NCT07053423	AEOLUSA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	P4	Chronic Obstructive Pulmonary Disease	218	Sep 2025
NCT06234761	Immunological Mechanisms Underlying Mucosal IgE Responses	—	Pathophysiology	50	Jan 2024
NCT06191315	LIBERTY ASTHMA TREKIDSEfficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)	P3	Wheezing	90	Jan 2024
NCT07112378	A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis	P3	Eosinophilic Esophagitis (EoE)	20	Nov 2025
NCT07587658	MISSIONThis After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization	P4	Chronic Obstructive Pulmonary Disease (COPD)	754	Jun 2026
NCT07276425	Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis	—	Prurigo Nodularis (PN)	40	Jun 2025
NCT06369467	Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy	P1	Food Allergy	6	May 2024
NCT07091175	SMART-NSDupilumab Therapy in Nephrotic Syndrome in Children	P2	Nephrotic Syndrome in Children	66	Nov 2025
NCT05858619	Molecular Signatures of Cutaneous Dupilumab Response	P4	Atopic Dermatitis	15	Feb 2023
NCT06385236	EPIPHANYLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping	P4	Moderate to Severe Asthma	120	Feb 2024
NCT07358234	Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.	Early P1	Eosinophilic Esophagitis (EoE)	60	Feb 2026
NCT07330934	A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis	P2	Atopic Dermatitis	403	Dec 2025
NCT06892704	Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.	—	Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)	30	May 2025
NCT07257835	Dupilumab Therapy for EGIDs	—	Eosinophilic Gastrointestinal Disorders (EGIDs)	20	Jan 2025
NCT05720325	Dupilumab Effects Against Aeroallergen Challenge	P2	Asthma, Allergic	88	Mar 2023
NCT06293053	A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis	P3	Prurigo Nodularis	18	May 2024
NCT05551793	Regeneron AA Multicenter (Dupilumab)	P2	Alopecia Areata	68	Apr 2023
NCT06398873	EpiBarEffect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP	—	Chronic Rhinosinusitis With Nasal Polyps	80	Jun 2024
NCT05263206	CPUOEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)	P3	Pruritus	284	Feb 2022
NCT05042258	Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis	P4	Atopic Dermatitis	40	Aug 2024
NCT05268107	Ethnic Differences in Mechanisms of Action of Dupilumab	P4	Atopic Dermatitis	30	Jan 2023
NCT05790330	Mind and Skin - the Neurocutaneous Axis in Atopic Eczema	—	Atopic Dermatitis	90	Mar 2023
NCT07399067	A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis	P2	Atopic Dermatitis	120	Feb 2026
NCT07467564	DERMIND-ADThe Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis	—	Atopic Dermatitis	184	Feb 2026
NCT06868212	RECLAIMA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	Chronic Spontaneous Urticaria (CSU)	400	Jul 2025
NCT06116526	Dupilumab De-escalation in Pediatric Atopic Dermatitis	P4	Atopic Dermatitis	30	Apr 2024
NCT06088771	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	P1/P2	Non-Small Cell Lung Cancer	21	Mar 2024
NCT06705387	DeTECTSDupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE	P2	Eosinophilic Esophagitis	72	Dec 2024
NCT06389136	Switch-UpA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	P3	Atopic Dermatitis	200	Jun 2024
NCT06477653	Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents	P2	Hypereosinophilic Syndrome	30	Feb 2025
NCT06637306	Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer	Early P1	Locally Advanced Triple Negative Breast Cancer	15	Mar 2025
NCT03936335	ADAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)	—	Adverse Pregnancy Outcomes	3,930	Sep 2019
NCT06226610	Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic	P2	Pruritis	46	Nov 2024
NCT07025200	DETACTDETACT sEvere asThmAtiC paTients - a Pilot Study	—	Asthma	10	Feb 2023
NCT06683261	RELIBIOReal-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)	—	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	300	Sep 2022
NCT05094570	Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP	P4	Nasal Polyps	20	Sep 2022
NCT04380038	VIAViral Infection in Asthma (VIA) Study	P4	Asthma	60	May 2022
NCT06087627	CLEAR PNA Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine	—	Prurigo Nodularis	150	Dec 2023
NCT06665971	Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)	P4	Eosinophilic Esophagitis (EoE)	30	Nov 2024
NCT04743791	MCCMeasuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma	P4	Asthma	30	Oct 2022
NCT06465732	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	P4	Atopic Dermatitis	220	Jan 2025
NCT07334496	A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects	P1	Biosimilarity	198	Mar 2026
NCT05246267	Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis	—	Chronic Rhinosinusitis With Nasal Polyps	60	Feb 2022
NCT06556264	Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps	P4	Chronic Rhinosinusitis With Nasal Polyps	60	Aug 2024
NCT06004986	DUPI REDUCEDUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema	P4	Atopic Dermatitis	216	Aug 2023
NCT06937788	Re-HU-TREATReplication of the Heads Up Atopic Dermatitis Trial With Registry Data	—	Atopic Dermatitis	240	Aug 2021
NCT06851403	The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study	—	Asthma in Children	213	Jan 2022
NCT04869436	Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis	P4	Chronic Rhinosinusitis With Nasal Polyps	27	Jul 2021

Dupilumab clinical trials by indication

Atopic Dermatitis (51)

NCT	Acronym	Phase	Status	Title
NCT07448363	—	N/A	not yet recruiting	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
NCT06461897	Start Up	P3	recruiting	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT03358693	MSID	N/A	recruiting	Molecular Signatures in Inflammatory Skin Disease
NCT06169527	DUPILAB	N/A	active not recruiting	A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
NCT05858619	—	P4	recruiting	Molecular Signatures of Cutaneous Dupilumab Response
NCT07330934	—	P2	recruiting	A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
NCT07027527	—	P1	active not recruiting	An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
NCT06415175	PROADAP	N/A	active not recruiting	Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
+ 43 more, see All trials below.

Asthma (26)

NCT	Acronym	Phase	Status	Title
NCT05097287	ATLAS	P4	active not recruiting	Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT06572228	AIM4:Next Step	P4	active not recruiting	Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT03694158	IDEA	P4	active not recruiting	Investigating Dupilumab's Effect in Asthma by Genotype
NCT05347771	PANDA	P2	active not recruiting	Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT07025200	DETACT	N/A	recruiting	DETACT sEvere asThmAtiC paTients - a Pilot Study
NCT04380038	VIA	P4	recruiting	Viral Infection in Asthma (VIA) Study
NCT04743791	MCC	P4	recruiting	Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04550962	REVEAL	N/A	active not recruiting	Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
+ 18 more, see All trials below.

Chronic Rhinosinusitis With Nasal Polyps (13)

NCT	Acronym	Phase	Status	Title
NCT06398873	EpiBar	N/A	recruiting	Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
NCT05228041	BIOPOSE	N/A	active not recruiting	BIOlogics in Severe Nasal POlyposis SurvEy
NCT06188871	—	P4	withdrawn	Early-onset Dupilumab Effects in CRSwNP
NCT05246267	—	N/A	recruiting	Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
NCT05942222	TORNADO	P4	active not recruiting	A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06556264	—	P4	not yet recruiting	Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
NCT04869436	—	P4	recruiting	Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
NCT05964465	—	P4	completed	Mechanisms of Smell Improvement With Dupilumab.
+ 5 more, see All trials below.

Dermatitis, Atopic (8)

NCT	Acronym	Phase	Status	Title
NCT03428646	PROSE	N/A	active not recruiting	Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
NCT06881251	DUPLEX-AD	P2	terminated	A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT04878770	—	N/A	unknown	NMF-CsA-Dupi Trial
NCT04791319	GENESIS	P2	terminated	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT03346434	Liberty AD	P2/P3	completed	Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
NCT03345914	TCS	P3	completed	Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
NCT02277743	SOLO 1	P3	completed	Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277769	SOLO 2	P3	completed	Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Eosinophilic Esophagitis (6)

NCT	Acronym	Phase	Status	Title
NCT06695897	ProMEAL	N/A	recruiting	A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
NCT06705387	DeTECTS	P2	recruiting	Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
NCT06352073	DESTRICT	P4	active not recruiting	Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT05247866	—	P4	completed	Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
NCT03633617	—	P3	completed	Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
NCT02379052	—	P2	completed	Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis (EoE) (5)

NCT	Acronym	Phase	Status	Title
NCT06693531	EDESIA	N/A	recruiting	A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT07112378	—	P3	recruiting	A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07358234	—	Early P1	enrolling by invitation	Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.
NCT06665971	—	P4	recruiting	Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT04394351	EoE KIDS	P3	completed	Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Dermatitis Atopic (5)

NCT	Acronym	Phase	Status	Title
NCT05983068	PELISTAD-EX2	P4	active not recruiting	A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
NCT03992417	GLOBOSTAD	N/A	active not recruiting	Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
NCT06192563	AD-BEASCUITS	N/A	unknown	A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
NCT04718870	PELISTAD	P4	completed	Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
NCT04823130	DIFFEREN-STAD	P4	completed	Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Chronic Spontaneous Urticaria (4)

NCT	Acronym	Phase	Status	Title
NCT07316114	DEDICATION	N/A	recruiting	A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
NCT05526521	CSU	P3	completed	A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
NCT04180488	LIBERTY-CSU CUPID	P3	completed	Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
NCT03749135	DUPICSU	P2	completed	Dupilumab in Chronic Spontaneous Urticaria

Nasal Polyps (4)

NCT	Acronym	Phase	Status	Title
NCT05094570	—	P4	recruiting	Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
NCT05575037	MARINER	P2	active not recruiting	Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
NCT06750471	—	P4	active not recruiting	Dupixent Study for Alternate Administration
NCT01920893	—	P2	completed	An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Healthy Volunteers (3)

NCT	Acronym	Phase	Status	Title
NCT07502534	—	P1	active not recruiting	A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
NCT05976386	—	P1	completed	Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults
NCT05976373	PK	P1	completed	A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

Chronic Obstructive Pulmonary Disease (3)

NCT	Acronym	Phase	Status	Title
NCT07053423	AEOLUS	P4	recruiting	A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT04456673	NOTUS	P3	completed	Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
NCT03930732	BOREAS	P3	completed	Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) (3)

NCT	Acronym	Phase	Status	Title
NCT06892704	—	N/A	recruiting	Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
NCT02898454	SINUS-52	P3	completed	Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
NCT02912468	SINUS-24	P3	completed	A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

Severe Asthma (3)

NCT	Acronym	Phase	Status	Title
NCT06818019	WIDUSA	P4	not yet recruiting	Withdrawal of Dupilumab in Severe Asthma
NCT05331755	RELYonDupi	N/A	completed	Real Life Experience Survey of Dupilumab in the Netherlands
NCT04022447	DUPI-France	N/A	completed	Dupilumab for Severe Asthma in a Real Life Setting

Alopecia Areata (3)

NCT	Acronym	Phase	Status	Title
NCT05866562	PEDAL	P2	recruiting	Dupilumab in the Treatment of Pediatric Alopecia Areata
NCT05551793	—	P2	recruiting	Regeneron AA Multicenter (Dupilumab)
NCT03359356	AA	P2	completed	Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Prurigo Nodularis (3)

NCT	Acronym	Phase	Status	Title
NCT06293053	—	P3	recruiting	A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
NCT06087627	CLEAR PN	N/A	recruiting	A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
NCT05991323	GLOBOSPIN	N/A	active not recruiting	Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Bullous Pemphigoid (3)

NCT	Acronym	Phase	Status	Title
NCT04206553	LIBERTY-BP	P2/P3	completed	A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
NCT05906706	—	N/A	approved for marketing	Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
NCT05649579	—	N/A	completed	Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

Atopic Dermatitis (AD) (3)

NCT	Acronym	Phase	Status	Title
NCT04173442	—	N/A	completed	Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
NCT03389893	—	P4	terminated	Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
NCT01979016	AD	P2	completed	Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Chronic Obstructive Pulmonary Disease (COPD) (2)

NCT	Acronym	Phase	Status	Title
NCT07052396	ANEMO	N/A	recruiting	Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
NCT07587658	MISSION	P4	not yet recruiting	This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

Non-Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06743581	Dupi-Cemi	N/A	not yet recruiting	Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
NCT06088771	—	P1/P2	recruiting	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Lichen Simplex Chronicus (2)

NCT	Acronym	Phase	Status	Title
NCT06687967	STYLE 1	P3	active not recruiting	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
NCT06687980	STYLE 2	P3	active not recruiting	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

Food Allergy (2)

NCT	Acronym	Phase	Status	Title
NCT06369467	—	P1	recruiting	Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT06631677	—	N/A	temporarily not available	Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (EgE)-Mediated Food Allergy Previously Treated With Linvoseltamab

Allergic Fungal Rhinosinusitis (2)

NCT	Acronym	Phase	Status	Title
NCT04684524	AFRS	P3	completed	Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)
NCT05545072	ADAPT	P3	terminated	Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

Asthma, Allergic (2)

NCT	Acronym	Phase	Status	Title
NCT05720325	—	P2	recruiting	Dupilumab Effects Against Aeroallergen Challenge
NCT03112577	—	P1	completed	Study of REGN3500 and Dupilumab in Patients With Asthma

Keloid (2)

NCT	Acronym	Phase	Status	Title
NCT05128383	—	P2	completed	Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
NCT04988022	—	P4	completed	Dupilumab in the Treatment of Keloids

Moderate-to-Severe Atopic Dermatitis (2)

NCT	Acronym	Phase	Status	Title
NCT05590585	DISCOVER	P4	completed	Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
NCT03054428	—	P3	completed	Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Pruritus (2)

NCT	Acronym	Phase	Status	Title
NCT05263206	CPUO	P3	recruiting	Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT04256759	—	P2	completed	Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Neurodermatitis (2)

NCT	Acronym	Phase	Status	Title
NCT04183335	LIBERTY-PN PRIME	P3	completed	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
NCT04202679	PRIME2	P3	completed	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Peanut Allergy (2)

NCT	Acronym	Phase	Status	Title
NCT03682770	—	P2	completed	Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
NCT03793608	—	P2	completed	Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07277322	—	P1/P2	not yet recruiting	Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Biosimilarity (1)

NCT	Acronym	Phase	Status	Title
NCT07334496	—	P1	not yet recruiting	A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

Asthma Control (1)

NCT	Acronym	Phase	Status	Title
NCT07309614	HOTHOT	P3	recruiting	A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Nephrotic Syndrome in Children (1)

NCT	Acronym	Phase	Status	Title
NCT07091175	SMART-NS	P2	recruiting	Dupilumab Therapy in Nephrotic Syndrome in Children

Severe Atopic Dermatitis (AD) (1)

NCT	Acronym	Phase	Status	Title
NCT07187089	BUILD-PEDS	P4	withdrawn	Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

Chronic Spontaneous Urticaria (CSU) (1)

NCT	Acronym	Phase	Status	Title
NCT06868212	RECLAIM	P3	recruiting	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Prurigo Nodularis (PN) (1)

NCT	Acronym	Phase	Status	Title
NCT07276425	—	N/A	recruiting	Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Locally Advanced Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06637306	—	Early P1	recruiting	Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Hypereosinophilic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06477653	—	P2	recruiting	Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Eosinophilic Gastrointestinal Disorders (EGIDs) (1)

NCT	Acronym	Phase	Status	Title
NCT07257835	—	N/A	recruiting	Dupilumab Therapy for EGIDs

Pruritis (1)

NCT	Acronym	Phase	Status	Title
NCT06226610	—	P2	recruiting	Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

Allergic Fungal Rhinosinusitis (AFRS) (1)

NCT	Acronym	Phase	Status	Title
NCT06461949	AFRS	P3	withdrawn	Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

Rhinosinusitis Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT06501807	BIOPOSE2	N/A	recruiting	BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry

Moderate to Severe Asthma (1)

NCT	Acronym	Phase	Status	Title
NCT06385236	EPIPHANY	P4	recruiting	Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

Healthy Participants (1)

NCT	Acronym	Phase	Status	Title
NCT06193434	FIH	P1	completed	A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Wheezing (1)

NCT	Acronym	Phase	Status	Title
NCT06191315	LIBERTY ASTHMA TREKIDS	P3	recruiting	Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Pathophysiology (1)

NCT	Acronym	Phase	Status	Title
NCT06234761	—	N/A	recruiting	Immunological Mechanisms Underlying Mucosal IgE Responses

Eosinophilic Oesophagitis (1)

NCT	Acronym	Phase	Status	Title
NCT06101095	—	P4	active not recruiting	A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Chronic Rhinosinusitis With Nasal Polyposis (1)

NCT	Acronym	Phase	Status	Title
NCT06393946	OPALE	N/A	active not recruiting	Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

Dermal Hypersensitivity Reaction (1)

NCT	Acronym	Phase	Status	Title
NCT06012448	—	P4	completed	The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

Asthma; Eosinophilic (1)

NCT	Acronym	Phase	Status	Title
NCT05787678	DEBORA	N/A	unknown	Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05967884	—	P2	unknown	PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Skin Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05649098	—	Early P1	recruiting	Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Eosinophilic Gastritis (EoG) (1)

NCT	Acronym	Phase	Status	Title
NCT05831176	ENGAGE	P2	active not recruiting	A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

Colitis Ulcerative (1)

NCT	Acronym	Phase	Status	Title
NCT05731128	—	P2	active not recruiting	A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Skin Inflammation (1)

NCT	Acronym	Phase	Status	Title
NCT05535738	—	P2/P3	active not recruiting	Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (1)

NCT	Acronym	Phase	Status	Title
NCT06683261	RELIBIO	N/A	recruiting	Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Eczema (1)

NCT	Acronym	Phase	Status	Title
NCT05265234	—	P4	unknown	Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

Asthma in Children (1)

NCT	Acronym	Phase	Status	Title
NCT06851403	—	N/A	enrolling by invitation	The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

Moderate-to-severe Atopic Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05203380	NEURADAD	N/A	completed	Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Allergies Food Milk (1)

NCT	Acronym	Phase	Status	Title
NCT04148352	—	P2	terminated	Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy

Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05013450	—	P1/P2	active not recruiting	Dupilumab_Metastatic NSCLC

COVID-19 (1)

NCT	Acronym	Phase	Status	Title
NCT04920916	SafeDrop	P2	completed	Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

Eosinophilic Gastritis (1)

NCT	Acronym	Phase	Status	Title
NCT03678545	—	P2	completed	Dupilumab in Eosinophilic Gastritis

Moderate to Severe Atopic Hand and Foot Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT04417894	—	P3	completed	A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Nummular Eczema (1)

NCT	Acronym	Phase	Status	Title
NCT04600362	DUPINUM	P2	active not recruiting	Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

Conjunctivitis (1)

NCT	Acronym	Phase	Status	Title
NCT04287608	—	N/A	completed	Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Congenital Ichthyosis (1)

NCT	Acronym	Phase	Status	Title
NCT04996485	—	P4	unknown	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis (1)

NCT	Acronym	Phase	Status	Title
NCT04430179	—	P2	active not recruiting	Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Cold Urticaria (1)

NCT	Acronym	Phase	Status	Title
NCT04681729	—	P3	completed	Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Chronic Rhinosinusitis Without Nasal Polyps (1)

NCT	Acronym	Phase	Status	Title
NCT04678856	Liberty CRSsNP	P3	completed	Dupilumab in CRSsNP

Chronic Sinusitis (1)

NCT	Acronym	Phase	Status	Title
NCT04362501	—	P2	completed	Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Allergic Bronchopulmonary Aspergillosis (1)

NCT	Acronym	Phase	Status	Title
NCT04442269	ABPA	P2	completed	Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Hand Eczema (1)

NCT	Acronym	Phase	Status	Title
NCT04512339	DUPSHE	P2	unknown	Dupilumab in Severe Chronic Hand Eczema

Netherton Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04244006	NS-DUPI	P2/P3	unknown	A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome

AERD - Aspirin Exacerbated Respiratory Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04442256	—	P4	unknown	Effect of Dupilumab on Aspirin Intolerance

Localized Scleroderma (1)

NCT	Acronym	Phase	Status	Title
NCT04200755	DupiMorph	P2	completed	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

Atopic Keratoconjunctivitis (1)

NCT	Acronym	Phase	Status	Title
NCT04296864	AKC	P2	unknown	Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Hypersensitivity (1)

NCT	Acronym	Phase	Status	Title
NCT03679676	COMBINE	P2	completed	Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Allergic Contact Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03935971	—	P4	active not recruiting	The Effects of Dupilumab on Allergic Contact Dermatitis

Adverse Pregnancy Outcomes (1)

NCT	Acronym	Phase	Status	Title
NCT03936335	AD	N/A	recruiting	An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03886493	—	P2	terminated	Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Chronic Hand Eczema (1)

NCT	Acronym	Phase	Status	Title
NCT03861455	DUPECZEMAIN	P2	completed	Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

Cholinergic Urticaria (1)

NCT	Acronym	Phase	Status	Title
NCT03749148	CHED	P2	completed	Cholinergic Urticaria - Efficacy of Dupilumab

Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03720470	JADE Compare	P3	completed	Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Aspirin-exacerbated Respiratory Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03595488	—	P2	completed	Dupilumab for Aspirin-exacerbated Respiratory Disease

Sleep Apnea (1)

NCT	Acronym	Phase	Status	Title
NCT03675022	—	Early P1	terminated	Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis

Allergic Rhinitis (1)

NCT	Acronym	Phase	Status	Title
NCT03558997	—	P2	completed	Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Atopic Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT03050151	—	P1	completed	Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Healthy Volunteer (1)

NCT	Acronym	Phase	Status	Title
NCT05976360	—	P1	completed	A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Type 2 Inflammatory Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT04776694	—	N/A	approved for marketing	Compassionate Use of Dupilumab

Dupilumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
WIDUSA	NCT06818019	P4	not yet recruiting	Severe Asthma	205	—
ATLAS	NCT05097287	P4	active not recruiting	Asthma	1,339	PMID 36891077
AEOLUS	NCT07053423	P4	recruiting	Chronic Obstructive Pulmonary Disease	218	—
MISSION	NCT07587658	P4	not yet recruiting	Chronic Obstructive Pulmonary Disease (COPD)	754	—
EPIPHANY	NCT06385236	P4	recruiting	Moderate to Severe Asthma	120	PMID 33385444
BUILD-PEDS	NCT07187089	P4	withdrawn	Severe Atopic Dermatitis (AD)	0	—
PELISTAD-EX2	NCT05983068	P4	active not recruiting	Dermatitis Atopic	48	—
AIM4:Next Step	NCT06572228	P4	active not recruiting	Asthma	120	—
IDEA	NCT03694158	P4	active not recruiting	Asthma	150	PMID 27479084
DESTRICT	NCT06352073	P4	active not recruiting	Eosinophilic Esophagitis	23	—
VIA	NCT04380038	P4	recruiting	Asthma	60	—
MCC	NCT04743791	P4	recruiting	Asthma	30	—
MADULO	NCT05642208	P4	active not recruiting	Atopic Dermatitis	256	PMID 41350756
TORNADO	NCT05942222	P4	active not recruiting	Chronic Rhinosinusitis With Nasal Polyps	220	—
DUPI REDUCE	NCT06004986	P4	recruiting	Atopic Dermatitis	216	—
LEADS	NCT05436535	P4	completed	Atopic Dermatitis	433	—
EVEREST	NCT04998604	P4	completed	Chronic Rhinosinusitis With Nasal Polyps	360	PMID 35837739
DISCOVER	NCT05590585	P4	completed	Moderate-to-Severe Atopic Dermatitis	124	—
PELISTAD CN	NCT05680298	P4	completed	Atopic Dermatitis	34	—
BALISTAD-CN	NCT05624112	P4	completed	Atopic Dermatitis	44	—
VESTIGE	NCT04400318	P4	completed	Asthma	109	PMID 39947221
SINUS-M52	NCT05049122	P4	completed	Chronic Rhinosinusitis With Nasal Polyps	25	PMID 40884290
IL	NCT05036733	P4	completed	Asthma	15	—
PELISTAD	NCT04718870	P4	completed	Dermatitis Atopic	41	PMID 41611123
DIFFEREN-STAD	NCT04823130	P4	completed	Dermatitis Atopic	54	—
BALISTAD	NCT04447417	P4	completed	Atopic Dermatitis	52	—
Start Up	NCT06461897	P3	recruiting	Atopic Dermatitis	675	—
HOTHOT	NCT07309614	P3	recruiting	Asthma Control	150	PMID 41967704
LIBERTY ASTHMA TREKIDS	NCT06191315	P3	recruiting	Wheezing	90	—
CPUO	NCT05263206	P3	recruiting	Pruritus	284	—
RECLAIM	NCT06868212	P3	recruiting	Chronic Spontaneous Urticaria (CSU)	400	PMID 41854973
Switch-Up	NCT06389136	P3	recruiting	Atopic Dermatitis	200	—
AD	NCT02612454	P3	active not recruiting	Atopic Dermatitis	880	PMID 41903092
STYLE 1	NCT06687967	P3	active not recruiting	Lichen Simplex Chronicus	142	—
STYLE 2	NCT06687980	P3	active not recruiting	Lichen Simplex Chronicus	138	—
AFRS	NCT04684524	P3	completed	Allergic Fungal Rhinosinusitis	62	—
CSU	NCT05526521	P3	completed	Chronic Spontaneous Urticaria	15	—
LIBERTY-CSU CUPID	NCT04180488	P3	completed	Chronic Spontaneous Urticaria	397	PMID 39066978
Level Up	NCT05601882	P3	completed	Atopic Dermatitis	920	PMID 41533220
AFRS	NCT06461949	P3	withdrawn	Allergic Fungal Rhinosinusitis (AFRS)	0	—
ADAPT	NCT05545072	P3	terminated	Allergic Fungal Rhinosinusitis	5	—
NOTUS	NCT04456673	P3	completed	Chronic Obstructive Pulmonary Disease	935	PMID 38767614
EoE KIDS	NCT04394351	P3	completed	Eosinophilic Esophagitis (EoE)	102	PMID 38924731
Liberty CRSsNP	NCT04678856	P3	completed	Chronic Rhinosinusitis Without Nasal Polyps	71	—
BOREAS	NCT03930732	P3	completed	Chronic Obstructive Pulmonary Disease	939	PMID 40024335
LIBERTY-PN PRIME	NCT04183335	P3	completed	Neurodermatitis	151	PMID 42120670
PRIME2	NCT04202679	P3	completed	Neurodermatitis	160	PMID 37142763
Heads Up	NCT03738397	P3	completed	Atopic Dermatitis	673	PMID 34347860
VOYAGE	NCT02948959	P3	completed	Asthma	408	PMID 37059696
JADE Compare	NCT03720470	P3	completed	Dermatitis	838	PMID 42084697
LIBERTY ASTHMA TRAVERSE	NCT02134028	P3	completed	Asthma	2,282	PMID 37780074
TCS	NCT03345914	P3	completed	Dermatitis, Atopic	367	PMID 34427891
SINUS-52	NCT02898454	P3	completed	Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)	448	PMID 34459002
SINUS-24	NCT02912468	P3	completed	Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)	276	PMID 35775319
VENTURE	NCT02528214	P3	completed	Asthma	210	PMID 35809937
AD	NCT02755649	P3	completed	Atopic Dermatitis	325	PMID 36723913
CHRONOS	NCT02260986	P3	completed	Atopic Dermatitis	740	PMID 33511576
SOLO-CONTINUE	NCT02395133	P3	completed	Atopic Dermatitis	422	PMID 31876900
SOLO 1	NCT02277743	P3	completed	Dermatitis, Atopic	671	PMID 27690741
SOLO 2	NCT02277769	P3	completed	Dermatitis, Atopic	708	PMID 31407311
PEDAL	NCT05866562	P2	recruiting	Alopecia Areata	76	—
SMART-NS	NCT07091175	P2	recruiting	Nephrotic Syndrome in Children	66	PMID 10073603
DeTECTS	NCT06705387	P2	recruiting	Eosinophilic Esophagitis	72	—
PANDA	NCT05347771	P2	active not recruiting	Asthma	240	—
DUPINUM	NCT04600362	P2	active not recruiting	Nummular Eczema	70	PMID 37119871
ENGAGE	NCT05831176	P2	active not recruiting	Eosinophilic Gastritis (EoG)	22	PMID 37753954
MARINER	NCT05575037	P2	active not recruiting	Nasal Polyps	17	—
DUPLEX-AD	NCT06881251	P2	terminated	Dermatitis, Atopic	256	—
COMBINE	NCT03679676	P2	completed	Hypersensitivity	130	—
AKC	NCT04296864	P2	unknown	Atopic Keratoconjunctivitis	42	—
ABPA	NCT04442269	P2	completed	Allergic Bronchopulmonary Aspergillosis	62	PMID 33027187
DUPECZEMAIN	NCT03861455	P2	completed	Chronic Hand Eczema	94	PMID 25244099
DupiMorph	NCT04200755	P2	completed	Localized Scleroderma	45	—
SafeDrop	NCT04920916	P2	completed	COVID-19	40	PMID 35959207
CHED	NCT03749148	P2	completed	Cholinergic Urticaria	48	—
DUPSHE	NCT04512339	P2	unknown	Hand Eczema	30	PMID 37170922
GENESIS	NCT04791319	P2	terminated	Dermatitis, Atopic	199	—
DUPICSU	NCT03749135	P2	completed	Chronic Spontaneous Urticaria	72	—
AA	NCT03359356	P2	completed	Alopecia Areata	60	PMID 34460948
EXPEDITION	NCT02573233	P2	completed	Asthma	42	—
AD	NCT02210780	P2	completed	Atopic Dermatitis	194	PMID 36525340
AD	NCT01979016	P2	completed	Atopic Dermatitis (AD)	54	PMID 30194992
TCS	NCT01639040	P2	completed	Atopic Dermatitis	31	PMID 25006719

Terminated and withdrawn Dupilumab trials (12)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT07187089withdrawnStudy of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
NCT06188871withdrawnEarly-onset Dupilumab Effects in CRSwNP
NCT06881251terminatedA Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT04148352terminatedDupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
NCT06461949withdrawnStudy of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
NCT05545072terminatedAdd-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
NCT03675022terminatedEffect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
NCT04791319terminatedA Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT03886493terminatedNeoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
NCT03389893terminatedEffect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
NCT03736967terminatedEfficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03411837terminatedDupilumab Phase 4 Study

All Dupilumab trials (230)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06501807	BIOPOSE2	BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry	N/A	recruiting	900	University Hospital, Lille	Jul 2024
NCT05649098		Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders	Early P1	recruiting	30	Northwestern University	Jun 2023
NCT07448363		Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	not yet recruiting	50	Caja Costarricense de Seguro Social	May 2026
NCT07277322		Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases	P1/P2	not yet recruiting	24	Dan Feng	Jun 2026
NCT06461897	Start Up	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	P3	recruiting	675	AbbVie	Aug 2024
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT06693531	EDESIA	A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care	—	recruiting	350	Regeneron Pharmaceuticals	Nov 2024
NCT06743581	Dupi-Cemi	Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer	N/A	not yet recruiting	24	Centre hospitalier de l'Université de Montréal (CHUM)	Feb 2025
NCT07309614	HOTHOT	A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma	P3	recruiting	150	Université de Sherbrooke	Jan 2026
NCT06818019	WIDUSA	Withdrawal of Dupilumab in Severe Asthma	P4	not yet recruiting	205	University Hospital, Toulouse	Apr 2025
NCT03358693	MSID	Molecular Signatures in Inflammatory Skin Disease	—	recruiting	300	Prof. Dr. Stephan Weidinger	Jan 2017
NCT07316114	DEDICATION	A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria	—	recruiting	400	Sanofi	Mar 2026
NCT07052396	ANEMO	Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions	—	recruiting	350	Sanofi	Jul 2025
NCT05097287	ATLAS	Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma	P4	active not recruiting	1,339	Sanofi	Dec 2021
NCT06695897	ProMEAL	A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany	—	recruiting	150	Sanofi	Dec 2024
NCT05866562	PEDAL	Dupilumab in the Treatment of Pediatric Alopecia Areata	P2	recruiting	76	Icahn School of Medicine at Mount Sinai	Jul 2024
NCT07053423	AEOLUS	A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	P4	recruiting	218	Sanofi	Sep 2025
NCT06234761		Immunological Mechanisms Underlying Mucosal IgE Responses	—	recruiting	50	University Hospital, Ghent	Jan 2024
NCT06191315	LIBERTY ASTHMA TREKIDS	Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)	P3	recruiting	90	Sanofi	Jan 2024
NCT07112378		A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis	P3	recruiting	20	Regeneron Pharmaceuticals	Nov 2025
NCT07587658	MISSION	This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization	P4	not yet recruiting	754	Regeneron Pharmaceuticals	Jun 2026
NCT07276425		Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis	—	recruiting	40	UMC Utrecht	Jun 2025
NCT06169527	DUPILAB	A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab	—	active not recruiting	303	Sanofi	Nov 2023
NCT06369467		Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy	P1	recruiting	6	Regeneron Pharmaceuticals	May 2024
NCT07091175	SMART-NS	Dupilumab Therapy in Nephrotic Syndrome in Children	P2	recruiting	66	National University Hospital, Singapore	Nov 2025
NCT06101095		A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)	P4	active not recruiting	69	Sanofi	Nov 2023
NCT05858619		Molecular Signatures of Cutaneous Dupilumab Response	P4	recruiting	15	University of California, San Francisco	Feb 2023
NCT06385236	EPIPHANY	Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping	P4	recruiting	120	University of California, San Diego	Feb 2024
NCT07187089	BUILD-PEDS	Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab	P4	withdrawn	0	Regeneron Pharmaceuticals	Nov 2025
NCT07358234		Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.	Early P1	enrolling by invitation	60	Mayo Clinic	Feb 2026
NCT07330934		A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis	P2	recruiting	403	Innovent Biologics (Suzhou) Co. Ltd.	Dec 2025
NCT07027527		An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis	P1	active not recruiting	86	Apogee Therapeutics, Inc.	Jun 2025
NCT06892704		Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.	—	recruiting	30	Northwestern University	May 2025
NCT05535738		Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation	P2/P3	active not recruiting	45	Wei-Che Ko	Nov 2022
NCT07257835		Dupilumab Therapy for EGIDs	—	recruiting	20	Children's Hospital of Fudan University	Jan 2025
NCT05720325		Dupilumab Effects Against Aeroallergen Challenge	P2	recruiting	88	The University of Texas Health Science Center at San Antonio	Mar 2023
NCT06415175	PROADAP	Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain	—	active not recruiting	143	Sanofi	Nov 2024
NCT06293053		A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis	P3	recruiting	18	Sanofi	May 2024
NCT05551793		Regeneron AA Multicenter (Dupilumab)	P2	recruiting	68	Emma Guttman	Apr 2023
NCT06398873	EpiBar	Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP	—	recruiting	80	Medical University of Vienna	Jun 2024
NCT05263206	CPUO	Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)	P3	recruiting	284	Sanofi	Feb 2022
NCT05228041	BIOPOSE	BIOlogics in Severe Nasal POlyposis SurvEy	—	active not recruiting	100	University Hospital, Lille	Feb 2022
NCT05042258		Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis	P4	recruiting	40	Northwestern University	Aug 2024
NCT05268107		Ethnic Differences in Mechanisms of Action of Dupilumab	P4	recruiting	30	University of Michigan	Jan 2023
NCT06188871		Early-onset Dupilumab Effects in CRSwNP	P4	withdrawn	0	University of Rochester	Jun 2024
NCT05790330		Mind and Skin - the Neurocutaneous Axis in Atopic Eczema	—	recruiting	90	King's College London	Mar 2023
NCT07399067		A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis	P2	recruiting	120	Innovent Biologics (Suzhou) Co. Ltd.	Feb 2026
NCT07467564	DERMIND-AD	The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis	—	recruiting	184	Sanofi	Feb 2026
NCT05983068	PELISTAD-EX2	A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis	P4	active not recruiting	48	Sanofi	Feb 2024
NCT06868212	RECLAIM	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	recruiting	400	Novartis Pharmaceuticals	Jul 2025
NCT06116526		Dupilumab De-escalation in Pediatric Atopic Dermatitis	P4	recruiting	30	Johns Hopkins University	Apr 2024
NCT06572228	AIM4:Next Step	Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma	P4	active not recruiting	120	Regeneron Pharmaceuticals	Aug 2024
NCT06088771		Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	P1/P2	recruiting	21	Icahn School of Medicine at Mount Sinai	Mar 2024
NCT06705387	DeTECTS	Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE	P2	recruiting	72	University of Colorado, Denver	Dec 2024
NCT06389136	Switch-Up	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	P3	recruiting	200	AbbVie	Jun 2024
NCT03694158	IDEA	Investigating Dupilumab's Effect in Asthma by Genotype	P4	active not recruiting	150	Boston Children's Hospital	Sep 2021
NCT03992417	GLOBOSTAD	Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)	—	active not recruiting	955	Sanofi	Jun 2019
NCT06477653		Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents	P2	recruiting	30	National Institute of Allergy and Infectious Diseases (NIAID)	Feb 2025
NCT03428646	PROSE	Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)	—	active not recruiting	858	Regeneron Pharmaceuticals	Apr 2018
NCT05347771	PANDA	Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents	P2	active not recruiting	240	National Institute of Allergy and Infectious Diseases (NIAID)	May 2022
NCT06637306		Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer	Early P1	recruiting	15	Rima Patel	Mar 2025
NCT05731128		A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))	P2	active not recruiting	68	Sanofi	Jan 2023
NCT04600362	DUPINUM	Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema	P2	active not recruiting	70	Technical University of Munich	Mar 2021
NCT03936335	AD	An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)	—	recruiting	3,930	Regeneron Pharmaceuticals	Sep 2019
NCT06226610		Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic	P2	recruiting	46	Akron Children's Hospital	Nov 2024
NCT06352073	DESTRICT	Dupilumab for Eosinophilic Esophagitis With Severe Strictures	P4	active not recruiting	23	University of North Carolina, Chapel Hill	May 2024
NCT07025200	DETACT	DETACT sEvere asThmAtiC paTients - a Pilot Study	—	recruiting	10	Medical University of Vienna	Feb 2023
NCT06683261	RELIBIO	Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)	—	recruiting	300	Universitaire Ziekenhuizen KU Leuven	Sep 2022
NCT05094570		Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP	P4	recruiting	20	University of Virginia	Sep 2022
NCT04380038	VIA	Viral Infection in Asthma (VIA) Study	P4	recruiting	60	University of Virginia	May 2022
NCT06087627	CLEAR PN	A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine	—	recruiting	150	Sanofi	Dec 2023
NCT05831176	ENGAGE	A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have	P2	active not recruiting	22	Regeneron Pharmaceuticals	May 2023
NCT06665971		Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)	P4	recruiting	30	University of California, San Diego	Nov 2024
NCT02612454	AD	Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)	P3	active not recruiting	880	Regeneron Pharmaceuticals	Oct 2015
NCT04743791	MCC	Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma	P4	recruiting	30	Sally E. Wenzel MD	Oct 2022
NCT05991323	GLOBOSPIN	Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study	—	active not recruiting	100	Sanofi	Dec 2023
NCT05642208	MADULO	Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis	P4	active not recruiting	256	Nantes University Hospital	Mar 2023
NCT06687967	STYLE 1	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)	P3	active not recruiting	142	Sanofi	Nov 2024
NCT06687980	STYLE 2	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)	P3	active not recruiting	138	Sanofi	Nov 2024
NCT06465732		Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	P4	not yet recruiting	220	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2025
NCT06393946	OPALE	Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France	—	active not recruiting	150	Sanofi	Oct 2023
NCT03935971		The Effects of Dupilumab on Allergic Contact Dermatitis	P4	active not recruiting	17	Brigham and Women's Hospital	Dec 2019
NCT07334496		A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects	P1	not yet recruiting	198	Gan & Lee Pharmaceuticals.	Mar 2026
NCT07502534		A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers	P1	active not recruiting	180	Innovent Biologics (Suzhou) Co. Ltd.	Apr 2026
NCT04550962	REVEAL	Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)	—	active not recruiting	376	Sanofi	Nov 2020
NCT05246267		Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis	—	recruiting	60	Montefiore Medical Center	Feb 2022
NCT05942222	TORNADO	A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps	P4	active not recruiting	220	Rigshospitalet, Denmark	Apr 2023
NCT05575037	MARINER	Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease	P2	active not recruiting	17	Brigham and Women's Hospital	Aug 2023
NCT06881251	DUPLEX-AD	A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)	P2	terminated	256	Janssen Research & Development, LLC	Feb 2025
NCT07574294	DREAM-NP	Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps	—	completed	205	Azienda Ulss 2 Marca Trevigiana	Jun 2025
NCT06192563	AD-BEASCUITS	A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment	—	unknown	150	Sanofi	Nov 2023
NCT06556264		Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps	P4	not yet recruiting	60	Dr. Andrew Thamboo, MD	Aug 2024
NCT06004986	DUPI REDUCE	DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema	P4	recruiting	216	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Aug 2023
NCT06750471		Dupixent Study for Alternate Administration	P4	active not recruiting	30	Madigan Army Medical Center	Oct 2021
NCT06937788	Re-HU-TREAT	Replication of the Heads Up Atopic Dermatitis Trial With Registry Data	—	recruiting	240	Technische Universität Dresden	Aug 2021
NCT06851403		The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study	—	enrolling by invitation	213	Guangzhou Institute of Respiratory Disease	Jan 2022
NCT05013450		Dupilumab_Metastatic NSCLC	P1/P2	active not recruiting	33	Thomas Marron	Sep 2021
NCT04869436		Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis	P4	recruiting	27	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Jul 2021
NCT04173442		Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy	—	completed	581	Regeneron Pharmaceuticals	Oct 2018
NCT05436535	LEADS	Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis	P4	completed	433	National Institute of Allergy and Infectious Diseases (NIAID)	Nov 2022
NCT04362501		Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)	P2	completed	33	Johns Hopkins University	Oct 2020
NCT06193434	FIH	A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients	P1	completed	99	Innovent Biologics (Suzhou) Co. Ltd.	Jan 2024
NCT04430179		Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis	P2	active not recruiting	30	University of South Florida	Dec 2020
NCT05128383		Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids	P2	completed	20	Beth Israel Deaconess Medical Center	Jan 2023
NCT03679676	COMBINE	Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)	P2	completed	130	Stanford University	Feb 2020
NCT03560466		Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)	P3	completed	378	Sanofi	Jun 2018
NCT06012448		The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction	P4	completed	10	University of Michigan	Oct 2023
NCT04988022		Dupilumab in the Treatment of Keloids	P4	completed	44	Icahn School of Medicine at Mount Sinai	May 2021
NCT04684524	AFRS	Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)	P3	completed	62	Sanofi	Dec 2020
NCT04148352		Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy	P2	terminated	33	Andrew J Long, PharmD	Oct 2021
NCT05526521	CSU	A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)	P3	completed	15	Sanofi	Aug 2022
NCT04296864	AKC	Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)	P2	unknown	42	Andover Eye Associates	Feb 2020
NCT05964465		Mechanisms of Smell Improvement With Dupilumab.	P4	completed	60	Medical University of South Carolina	Aug 2023
NCT05247866		Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis	P4	completed	21	Children's Hospital of Philadelphia	Jun 2022
NCT04206553	LIBERTY-BP	A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid	P2/P3	completed	106	Regeneron Pharmaceuticals	Oct 2020
NCT04878770		NMF-CsA-Dupi Trial	N/A	unknown	318	Erasmus Medical Center	Aug 2021
NCT05787678	DEBORA	Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion	—	unknown	30	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Oct 2023
NCT04998604	EVEREST	EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients	P4	completed	360	Sanofi	Sep 2021
NCT05878093		Dupilumab in Chinese Adult Participants With CRSwNP	P3	completed	63	Sanofi	May 2023
NCT05590585	DISCOVER	Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial	P4	completed	124	Regeneron Pharmaceuticals	Jan 2023
NCT03678545		Dupilumab in Eosinophilic Gastritis	P2	completed	41	Children's Hospital Medical Center, Cincinnati	May 2021
NCT04180488	LIBERTY-CSU CUPID	Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)	P3	completed	397	Sanofi	Dec 2019
NCT06631677		Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (EgE)-Mediated Food Allergy Previously Treated With Linvoseltamab	—	temporarily not available	0	Regeneron Pharmaceuticals	—
NCT04256759		Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus	P2	completed	9	Mayo Clinic	Sep 2020
NCT05601882	Level Up	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	920	AbbVie	Nov 2022
NCT05967884		PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer	P2	unknown	20	Ottawa Hospital Research Institute	Aug 2023
NCT06461949	AFRS	Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray	P3	withdrawn	0	National Institute on Deafness and Other Communication Disorders (NIDCD)	Jul 2024
NCT05545072	ADAPT	Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)	P3	terminated	5	Emory University	Oct 2023
NCT04244006	NS-DUPI	A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome	P2/P3	unknown	24	University Hospital, Toulouse	Jul 2020
NCT04456673	NOTUS	Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation	P3	completed	935	Sanofi	Jul 2020
NCT04394351	EoE KIDS	Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)	P3	completed	102	Regeneron Pharmaceuticals	Sep 2020
NCT04596189		Dupilumab for Prevention of Recurrence of CRSwNP After ESS	P4	completed	30	Centre hospitalier de l'Université de Montréal (CHUM)	May 2021
NCT06509243	DuHDM	Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis	N/A	completed	132	Medical University of Silesia	Feb 2023
NCT05680298	PELISTAD CN	Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China	P4	completed	34	Sanofi	Feb 2023
NCT05265234		Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.	P4	unknown	15	OptiSkin Medical	Mar 2022
NCT05372003		IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis	Early P1	completed	7	Mayo Clinic	Aug 2022
NCT04442269	ABPA	Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)	P2	completed	62	Regeneron Pharmaceuticals	Sep 2020
NCT04678856	Liberty CRSsNP	Dupilumab in CRSsNP	P3	completed	71	Sanofi	Dec 2020
NCT05624112	BALISTAD-CN	Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China	P4	completed	44	Sanofi	Nov 2022
NCT03861455	DUPECZEMAIN	Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids	P2	completed	94	University Hospital, Toulouse	Jul 2019
NCT04200755	DupiMorph	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma	P2	completed	45	University of Cologne	May 2020
NCT04678882		Dupilumab in Japanese Patients With Atopic Dermatitis	P3	completed	62	Sanofi	Jan 2021
NCT05529784	DUPIREAL	Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)	—	unknown	600	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Oct 2021
NCT04400318	VESTIGE	The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma	P4	completed	109	Sanofi	Jun 2020
NCT04895423		Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood	P4	unknown	160	National Medical Research Center for Children's Health, Russian Federation	Nov 2021
NCT04203797		A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma	P4	completed	40	Regeneron Pharmaceuticals	Jul 2020
NCT05049122	SINUS-M52	Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)	P4	completed	25	Sanofi	Oct 2021
NCT05036733	IL	Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma	P4	completed	15	University of Michigan	Feb 2022
NCT05906706		Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid	—	approved for marketing	0	Regeneron Pharmaceuticals	—
NCT04996485		Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children	P4	unknown	50	National Medical Research Center for Children's Health, Russian Federation	Mar 2021
NCT03930732	BOREAS	Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation	P3	completed	939	Sanofi	Apr 2019
NCT04681729		Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)	P3	completed	82	Sanofi	Dec 2020
NCT04920916	SafeDrop	Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients	P2	completed	40	University of Virginia	May 2021
NCT04287608		Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis	—	completed	50	Regeneron Pharmaceuticals	Mar 2021
NCT05203380	NEURADAD	Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis	—	completed	45	Regeneron Pharmaceuticals	Jan 2022
NCT03749148	CHED	Cholinergic Urticaria - Efficacy of Dupilumab	P2	completed	48	Charite University, Berlin, Germany	Dec 2018
NCT03293030		Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis	P4	completed	17	University of California, San Francisco	Oct 2018
NCT05649579		Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid	—	completed	146	Peking University First Hospital	Sep 2022
NCT03884842		Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.	P3	completed	24	McMaster University	Jul 2019
NCT05331755	RELYonDupi	Real Life Experience Survey of Dupilumab in the Netherlands	—	completed	120	Gert-Jan Braunstahl	Apr 2021
NCT04442256		Effect of Dupilumab on Aspirin Intolerance	P4	unknown	30	Medical University of Vienna	Jun 2020
NCT03667014		The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients	P4	completed	34	University of California, San Francisco	Nov 2018
NCT04665141		Similarities and Differences of Biological Therapies for Severe Asthma.	—	unknown	600	Clinica Universidad de Navarra, Universidad de Navarra	Apr 2021
NCT04718870	PELISTAD	Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis	P4	completed	41	Sanofi	Feb 2021
NCT04417894		A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)	P3	completed	133	Regeneron Pharmaceuticals	Apr 2021
NCT04358224		The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment	P4	completed	12	Jonathan A. Bernstein, MD	Sep 2020
NCT04512339	DUPSHE	Dupilumab in Severe Chronic Hand Eczema	P2	unknown	30	University Medical Center Groningen	Aug 2020
NCT04823130	DIFFEREN-STAD	Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis	P4	completed	54	Sanofi	Apr 2021
NCT03675022		Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis	Early P1	terminated	9	Brigham and Women's Hospital	Aug 2018
NCT01949311		Open-label Study of Dupilumab in Patients With Atopic Dermatitis	P3	completed	2,733	Regeneron Pharmaceuticals	Oct 2013
NCT03633617		Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)	P3	completed	321	Regeneron Pharmaceuticals	Sep 2018
NCT03782532		Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma	P3	completed	486	Sanofi	Jan 2019
NCT04791319	GENESIS	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis	P2	terminated	199	Janssen Research & Development, LLC	May 2021
NCT03620747		Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)	P3	completed	393	Sanofi	Aug 2018
NCT04183335	LIBERTY-PN PRIME	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)	P3	completed	151	Sanofi	Dec 2019
NCT04202679	PRIME2	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)	P3	completed	160	Sanofi	Jan 2020
NCT04033367		SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"	P4	completed	188	Sanofi	Aug 2019
NCT03983460	DupiTrem	Dupilumab Impact on Skin Resident Memory T Cells	N/A	unknown	20	Association pour la Recherche Clinique et Immunologique	Mar 2020
NCT05976386		Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults	P1	completed	182	Sanofi	Jun 2021
NCT03682770		Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)	P2	completed	148	Regeneron Pharmaceuticals	Oct 2018
NCT04345367		Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	P3	completed	727	Pfizer	Jun 2020
NCT03346434	Liberty AD	Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)	P2/P3	completed	202	Regeneron Pharmaceuticals	Nov 2017
NCT03749135	DUPICSU	Dupilumab in Chronic Spontaneous Urticaria	P2	completed	72	Charite University, Berlin, Germany	Nov 2018
NCT04447417	BALISTAD	Dupilumab Skin Barrier Function Study in Atopic Dermatitis	P4	completed	52	Sanofi	Jul 2020
NCT03793608		Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy	P2	completed	25	Regeneron Pharmaceuticals	Mar 2019
NCT04520308		An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis	P4	unknown	45	Eric Simpson	Sep 2020
NCT04776694		Compassionate Use of Dupilumab	—	approved for marketing	0	Regeneron Pharmaceuticals	—
NCT03359356	AA	Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)	P2	completed	60	Icahn School of Medicine at Mount Sinai	Jan 2018
NCT03738397	Heads Up	A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	673	AbbVie	Feb 2019
NCT03886493		Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer	P2	terminated	7	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Aug 2019
NCT03389893		Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis	P4	terminated	72	National Institute of Allergy and Infectious Diseases (NIAID)	Jul 2018
NCT02948959	VOYAGE	Evaluation of Dupilumab in Children With Uncontrolled Asthma	P3	completed	408	Sanofi	Apr 2017
NCT03736967		Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis	P2	terminated	206	Regeneron Pharmaceuticals	Nov 2018
NCT03720470	JADE Compare	Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	P3	completed	838	Pfizer	Oct 2018
NCT03912259		Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis	P3	completed	165	Sanofi	Dec 2018
NCT03595488		Dupilumab for Aspirin-exacerbated Respiratory Disease	P2	completed	11	Rochester General Hospital	Sep 2018
NCT03112577		Study of REGN3500 and Dupilumab in Patients With Asthma	P1	completed	32	Regeneron Pharmaceuticals	Jun 2017
NCT02134028	LIBERTY ASTHMA TRAVERSE	Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)	P3	completed	2,282	Sanofi	Aug 2014
NCT03345914	TCS	Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)	P3	completed	367	Regeneron Pharmaceuticals	Nov 2017
NCT03411837	DRS	Dupilumab Phase 4 Study	—	terminated	46	Northwestern University	Oct 2017
NCT03387852		Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants	P2	completed	296	Sanofi	Mar 2018
NCT03558997		Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy	P2	completed	103	Regeneron Pharmaceuticals	Jun 2018
NCT04022447	DUPI-France	Dupilumab for Severe Asthma in a Real Life Setting	—	completed	86	Assistance Publique - Hôpitaux de Paris	Aug 2018
NCT02898454	SINUS-52	Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps	P3	completed	448	Sanofi	Nov 2016
NCT02912468	SINUS-24	A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps	P3	completed	276	Sanofi	Dec 2016
NCT03054428		Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis	P3	completed	251	Regeneron Pharmaceuticals	Mar 2017
NCT03050151		Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis	P1	completed	176	Regeneron Pharmaceuticals	Feb 2017
NCT02573233	EXPEDITION	Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma	P2	completed	42	Sanofi	Jan 2016
NCT02414854		Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)	P3	completed	1,902	Sanofi	Apr 2015
NCT02528214	VENTURE	Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma	P3	completed	210	Sanofi	Oct 2015
NCT02379052		Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)	P2	completed	47	Regeneron Pharmaceuticals	May 2015
NCT02755649	AD	A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable	P3	completed	325	Regeneron Pharmaceuticals	Jan 2016
NCT03020810		Dupilumab Compassionate Use Study	—	approved for marketing	0	Sally E. Wenzel MD	—
NCT02260986	CHRONOS	Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis	P3	completed	740	Regeneron Pharmaceuticals	Sep 2014
NCT02395133	SOLO-CONTINUE	A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)	P3	completed	422	Regeneron Pharmaceuticals	Mar 2015
NCT02647086	DDI	Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)	P1	completed	14	Regeneron Pharmaceuticals	Dec 2015
NCT02407756		A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)	P2	completed	78	Regeneron Pharmaceuticals	Mar 2015
NCT02277743	SOLO 1	Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis	P3	completed	671	Regeneron Pharmaceuticals	Oct 2014
NCT02277769	SOLO 2	Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis	P3	completed	708	Regeneron Pharmaceuticals	Nov 2014
NCT02210780	AD	Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)	P2	completed	194	Regeneron Pharmaceuticals	Aug 2014
NCT01854047		An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma	P2	completed	776	Sanofi	Jun 2013
NCT05976373	PK	A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.	P1	completed	38	Sanofi	Jan 2015
NCT01979016	AD	Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)	P2	completed	54	Regeneron Pharmaceuticals	Dec 2013
NCT05976360		A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants	P1	completed	38	Sanofi	Nov 2014
NCT01920893		An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis	P2	completed	60	Sanofi	Aug 2013
NCT01859988		Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis	P2	completed	380	Regeneron Pharmaceuticals	May 2013
NCT01548404		Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	P2	completed	109	Regeneron Pharmaceuticals	Apr 2012
NCT01639040	TCS	Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)	P2	completed	31	Regeneron Pharmaceuticals	Jul 2012
NCT01312961		Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	P2	completed	104	Sanofi	Mar 2011
NCT01385657		Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	P1	completed	37	Regeneron Pharmaceuticals	Jul 2011

Dupilumab clinical trials: frequently asked questions

How many Dupilumab clinical trials are there?: 230 Dupilumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 54 are actively recruiting participants. 105 are marked completed.
Are Dupilumab clinical trials recruiting in 2026?: Yes — 54 Dupilumab trials are actively recruiting in 2026, with 346 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Dupilumab being studied for?: Dupilumab is being studied for Atopic Dermatitis, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Dermatitis, Atopic, Eosinophilic Esophagitis and 130 more. The trials are grouped by indication on this page.
What phase is Dupilumab in?: Dupilumab clinical trials span 56 Phase 4, 50 Phase 3, 51 Phase 2, 12 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Dupilumab clinical trials?: The lead sponsor across the most Dupilumab trials is Sanofi, with 85 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Dupilumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Dupilumab overview Dupilumab evidence & publications